Natale Ricciardi has joined the board of Dynavax Technologies two years after retiring from Pfizer.
Ricciardi spent 39 years at Pfizer, advancing to president of the pharma giant’s global manufacturing business and senior VP of its North American operations.
He was also a member of the Pfizer executive leadership team when he retired in 2011.
Dynavax, which focuses on developing products to prevent and treat infectious and inflammatory diseases, will benefit from this senior experience as it looks to bring to market its lead product candidate, the hepatitis B vaccine Heplisav.
“On behalf of Dynavax, we are delighted to welcome Nat to the board,” said Arnold Oronsky, chairman of the board at Dynavax.
“His experienced leadership, particularly in global manufacturing, will provide valuable insight to the company and we look forward to his contributions.”